Detailly, the incidence of MET amplification in NSCLC patients resistant to third-generation EGFR-TKIs increased from 5-22% to 5-50% compared to the patients’ resistance to the first/second-generation EGFR-TKIs (16). This evidence concerns the gene MET and non-small cell lung carcinoma.